Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
This is a single-center, single arm, dose finding study to assess safety and tolerability of
the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in
chronic and accelerated phase.